Biomx Ltd is a biotechnology company focused on developing innovative therapies that harness the power of bacteriophage, a type of virus that specifically targets and kills bacteria. The company primarily aims to treat diseases caused by specific bacterial infections, particularly those that are resistant to traditional antibiotics. By utilizing phage-based treatments, Biomx is working to address significant medical challenges in various conditions, including gastrointestinal disorders and other diseases driven by harmful bacteria, with the ultimate goal of improving patient outcomes and enhancing the overall landscape of antimicrobial therapies. Read More
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company, offers rapid, intelligent, and non-invasive testing solutions. On May 29, the company announced its success in recruiting and starting the screening of subjects for its pharmacokinetic (PK) study. This study is a crucial step in Intelligent Bio Solutions' FDA 510(k) regulatory clearance process. The dedicated team worked diligently to ensure the study's design met FDA standards.
Companies Reporting Before The Bell • Acuity Brands (NYSE:AYI) is projected to report quarterly earnings at $3.25 per share on revenue of $907.75 million.
BiomX shares are trading higher Wednesday after the company announced it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. The acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions.
